Kymera Therapeutics KYMR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's cash & equivalents?
- Kymera Therapeutics (KYMR) reported cash & equivalents of $144.09M in Q1 2026.
- How has Kymera Therapeutics's cash & equivalents changed year-over-year?
- Kymera Therapeutics's cash & equivalents increased by 60.2% year-over-year, from $89.97M to $144.09M.
- What is the long-term trend for Kymera Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Kymera Therapeutics's cash & equivalents has grown at a 63.0% compound annual growth rate (CAGR), from $31M to $357.01M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.